A325 patients at risk for COPD (aged 45 ≤ years ≤ 85, ≥15 pack years) were included. Lung function (FEV1 and FEV6) was measured by copd-6 (mini-spirometer, Vitalograph), followed by ordinary spirometry (COPD diagnosis FEV1/FVC post bronchodilation ratio <70). Time consumed was recorded and costs calculated (national average nurse wage). Univariate logistic regression and receiver operating characteristic (ROC) curves were utilized. RESULTS: In all, 305 patients (21 centers in Sweden), females 57%, mean (standard deviation, SD) age 61.2 (8.4) years, FEV1/FVC 75.3 (10.2), pack years 30.3 (11.5) were included. COPD was diagnosed in 83 patients (27.2%). Copd-6 screening signifi cantly predicted COPD by FEV1/FEV6 ratio. Patients with COPD had a mean (SD) FEV1/FEV6 of 69.0 (9.1), patients without COPD 77.7 (9.6). Sensitivity and specifi city at a FEV1/FEV6 cut-off of 73.0 was 73.5% and 79.7%, respectively; area under the ROC curve was 0.800. Cost of one copd-6 measurement (~4 minutes) was SEK 19 (≈c2), while the cost for an ordinary spirometry (~33 minutes) was SEK 147 (≈c15). Without copd-6 pre-screening the cost of detecting one COPD patient based on age and pack years was SEK 542 (≈c54). Use of copd-6 reduces the cost to SEK 283 (≈c28), but also results in an 8.4% lower COPD detection rate due to copd-6 sensitivity limitations. CONCLUSIONS: Pre-screening with the copd-6 mini-spirometer to select patients (≥45 years; ≥15 pack years) for ordinary spirometry increased the frequency of detected COPD diagnoses from 27.2% to 73.5%. Although copd-6 sensitivity and specifi city could be improved, its use in primary care may reduce the costs of detecting COPD patients.
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Universitat de Barcelona, Barcelona, Spain; 2 BCN Health, Barcelona, Spain OBJECTIVES: To estimates cost and effectiveness of beclomethasone/formoterol extrafi ne, fl uticasone/salmeterol and budesodine/formoterol in the treatment of moderate to severe persistent asthma in Spain. METHODS: A Markov model was developed to represent the transition of a cohort of patients with moderate to severe persistent asthma through different health states: patients free of symptoms, patients with exacerbations and patients without exacerbations. Effi cacy data was obtained from observational studies. Deterministic results were estimated and a probabilistic sensitivity analysis was conducted using statistical distributions in order to capture parameter uncertainty in the decision model. Treatment costs were obtained from literature review and a panel of clinical experts. Costs were referred to year 2009 and a time horizon of 12 weeks was chosen. Results were presented as expected cost per QALY and represented in cost-effectiveness acceptability curves (CEACs). RESULTS: In the deterministic analysis, the expected cost per patient was greater in the fl uticasone/ salmeterol cohort (c333) and the budesodine/formoterol cohort (c300) in comparison with the beclomethasone/formoterol cohort (c292). The estimated effectiveness was the same in the three cohorts. In the probabilistic analysis CEACs showed that the probability that the treatment with beclomethasone/formoterol was more cost-effective than the treatment with fl uticasone/salmeterol and budesodine/formoterol using alternative values for the maximum value that the health service would be willing to pay for an additional QALY gained was greater in the beclomethasone/formoterol cohort. CONCLUSIONS: When beclomethasone/formoterol extrafi ne has been compared to fl uticasone/salmeterol and budesodine/formoterol we may conclude that the fi rst one is a dominant strategy. Results from probabilistic sensibility analysis show that the choice of optimal strategy is independent on the maximum that the health service is prepared to pay per additional QALY gained because beclomethasone/formoterol extrafi ne has a greater probability of being cost-effective for all threshold values.
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PRS36 ADHERENCE TO MEDICATION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH COPD: SGRQ-AN ALTERNATIVE METHOD TO IDENTIFY NONADHERENCE
Meszaros A, Agh T Semmelweis University, Budapest, Hungary OBJECTIVES: Medication adherence and health-related quality of life (HRQoL) are important factors in determining success of drug treatments; although both have been studied intensively, limited data is available on the association between these factors. This study aimed: 1) to assess the relationship between adherence and HRQoL in COPD patients using generic and disease specifi c instruments; and 2) to evaluate the association between adherence and answers of SGRQ part 2-section 5 referring to medication use. METHODS: The cross-sectional study included a post-bronchodilator spirometry and completion of a self reported postal questionnaire. Information on adherence (4-item Morisky Medication Adherence Scale) and HRQoL (generic: EuroQol-EQ-5D, disease specifi c: St. George's Respiratory Questionnaire-SGRQ) were obtained. Multiple linear regression model was used to analyze the association between HRQoL as dependent variable and disease severity (FEV1), age and adherence as independent variables. Differences in answers of SGRQ part 2-section 5 between adherence stages were analyzed with Pearson Chi-square test. RESULTS: A total of 227 patients were included at baseline, 170 of them completed the study. The mean age was 63.83 (SD = 11.24) years, there were slightly more female patients (58%). a total of 32% (n = 55) of the participants reported themselves as high adherent, 26% (n = 44) were medium, and 42% (n = 71) were low adherent. The mean EQ-5D score was 0.55 (SD = 0.21) and the mean SGRQ total score was 56.22% (SD = 16.19).
HRQoL assessed with EQ-5D and SGRQ were neither signifi cantly related to medication adherence. Both generic and disease-specifi c HRQoL were associated with age and disease severity. We found signifi cant association between the number of the positive answers' of SGRQ part 2-section 5 and adherence rate (Chi-square = 30.64 p = 0.000). CONCLUSIONS: The study showed no signifi cant relationship between adherence to medication and any HRQoL domain. Our results suggest that, SGRQ part 2-section 5 could be suitable to estimate adherence in patients with COPD in clinical practice.
PRS37
ASSOCIATION OF PATIENT-REPORTED INHALER SATISFACTION WITH PHYSICIAN-PERCEIVED COMPLIANCE WITH ASTHMA TREATMENT-RESULTS OF A CROSS-SECTIONAL STUDY IN FIVE EUROPEAN COUNTRIES
Small M, Piercy J, Anderson P, Vickers A Adelphi Real World, Macclesfi eld, Cheshire, UK OBJECTIVES: It is hypothesised that patient satisfaction with the features of an asthma inhaler directly infl uences compliance behaviour of asthma patients. This study investigated the relationship between physician-reported compliance of 1400 asthma patients with the degree of patient-reported satisfaction with their inhaler. METHODS: Data were drawn from the Adelphi Disease Specifi c Programme (DSP) in Asthma, a cross-sectional study of consulting patients undertaken in 2009. Data were collected from physicians for each patient and collected directly from consenting patients. Key factors analyzed were physician-reported perceptions of patient compliance on a 1-5 scale (where 1 is 'not at all compliant' and 5 is 'fully compliant') and data for patientreported satisfaction with their inhaler including specifi c device features associated with convenience, dosing and inhaler mechanism. The results were tested against potential confounders including age, gender, ethnicity and current asthma severity, to ensure the relationship effect between compliance and satisfaction was distinct. RESULTS: There was a signifi cant relationship between the physician-reported level of compliance and patient-reported satisfaction with their inhaler device. The investigators observed that a better perceived level of compliance was directly associated with a higher level of inhaler satisfaction (P < 0.001). Those inhaler features associated with convenience: "built to last/will not break easily"; "easy to hold and carry," "instructions are simple and easy to follow," and "no need to put the drug into the inhaler before use" accounted for four of the top fi ve drivers of overall satisfaction. CONCLUSIONS: Patient satisfaction with features of their inhaler is an important factor in promoting patient compliance. If physicians made particular effort to select an inhaler that satisfi es the patient, including attention to features associated with convenience, patient compliance with their asthma treatment would be expected to improve.
PRS38 SYMPTOMATIC COMORBIDITIES AND HEALTH-RELATED QUALITY OF LIFE IN COPD IN THE EUROPEAN UNION
Langley PC 1 , Freedman D 2 , Wagner JS 3 1 University of Minnesota, Minneapolis, MN, USA; 2 Kantar Health, Princeton, NJ, USA; 3 Kantar Health, New York, NY, USA OBJECTIVES: This study assesses the impact of high prevalence comorbidities reported by persons with diagnosed COPD on their health related quality of life (HRQoL). The focus is on (1) the quantitative impact of comorbidities on SF-6D utility scores, and (2) the relative impact of symptomatic vs. non-symptomatic comorbid disease states. METHODS: The study is based on data from the internet based 2008 National Health and Wellness Survey (NHWS) undertaken in the UK, France, Spain, Germany, and Italy. The study identifi ed 3103 persons with diagnosed COPD together with the nine most frequently diagnosed comorbidities: pain, high blood pressure, anxiety, high cholesterol, heartburn, insomnia, depression, migraine, and arthritis. High blood pressure and high cholesterol are considered non-symptomatic comorbidities. The impact of these comorbidities on the SF-6D utility scores (range 0-1) is estimated via an ordinary least squares regression model. All comorbidities enter as categorical variables. The model includes a range of variables which have been shown in previous studies to impact HRQoL. These include: sociodemographic factors, health risk behaviors (BMI, alcohol use, smoking), and a series of country dummy variables (Germany as reference category). RESULTS: The model demonstrates that for symptomatic comorbidites the impact on utility scores is substantial. All symptomatic comorbidities are signifi cant. Depression followed by pain experienced in the past 6 months have the greatest defi cit impact (respectively −0.060; 95% CI −0.071 to −0.050 and −0.055; 95% CI −0.064 to −0.045). High blood pressure and high cholesterol are not signifi cant. CONCLUSIONS: Claims for the negative impact of COPD on HRQoL should be seen in the context of a cluster of comorbid disease states; in particular the high prevalence disease states such a pain, anxiety and depression.
